1851 Harbor Bay Parkway
820 articles about Exelixis, Inc.
Exelixis Announces Preliminary Fourth Quarter and Full Year 2022 Financial Results, Provides 2023 Financial Guidance, and Outlines Key Priorities and Milestones for 2023
Exelixis, Inc. announced its preliminary unaudited financial results for the fourth quarter and full year 2022, provided financial guidance for full year 2023, and delivered an update on its business.
Exelixis to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023
Exelixis, Inc. announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer, will provide a corporate overview at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 8:15pm ET / 5:15pm PT.
Exelixis Announces Initiation of the STELLAR-304 Phase 3 Pivotal Trial Evaluating Zanzalintinib in Patients with Advanced Non-Clear Cell Kidney Cancer
Exelixis, Inc. (Nasdaq: EXEL) today announced the initiation of STELLAR-304, a phase 3 pivotal trial evaluating zanzalintinib in combination with nivolumab versus sunitinib in patients with advanced non-clear cell renal cell carcinoma (nccRCC).
A combination of Exelixis' cabozantinib and Roche's Tecentriq missed the primary endpoint of overall survival in a Phase III study.
Exelixis Provides Update on Phase 3 CONTACT-01 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Metastatic Non-Small Cell Lung Cancer Previously Treated with Immunotherapy and Chemotherapy
Exelixis, Inc. (Nasdaq: EXEL) today announced that the CONTACT-01 study did not meet its primary endpoint of overall survival at the final analysis. CONTACT-01 is a phase 3 trial evaluating cabozantinib (CABOMETYX®).
Exelixis Announces Initial Dose-Escalation Results from the First-in-Human Phase 1 Trial Evaluating XL102 in Patients with Advanced Solid Tumors at SABCS 2022
Exelixis, Inc. (Nasdaq: EXEL) today announced initial results from the ongoing dose-escalation stage of QUARTZ-101, a phase 1 clinical trial evaluating XL102, a potent, selective, irreversible and orally bioavailable small molecule cyclin-dependent kinase 7 (CDK7) inhibitor, in patients with advanced solid tumors.
Exelixis to Present at the Virtual JMP Securities Hematology and Oncology Summit on December 7, 2022
Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in a fireside chat at the virtual JMP Securities Hematology and Oncology Summit on Wednesday, December 7, 2022 at 12:00 pm ET / 9:00 am PT.
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in November 2022
Exelixis, Inc. announced that members of the company’s management team will participate in fireside chats at the following investor conferences in November.
Exelixis has inked a licensing agreement with Catalent to gain access to three of Catalent’s target programs with antibody and ADC candidates, the companies announced Thursday.
Exelixis and Catalent Enter into New License Agreement for Three Antibody-Drug Conjugate Programs with the Potential to Accelerate Exelixis’ Biologics Pipeline
Exelixis, Inc. (Nasdaq: EXEL) and Catalent, Inc. (NYSE: CTLT) today announced a new license agreement under which Catalent’s Redwood Bioscience subsidiary will grant Exelixis an exclusive license to three target programs with lead antibody and/or ADC candidates.
Flush with cash from the growing success of its chemotherapy drug, Exelixis dropped $100M on two collaboration deals this week to invest in promising early clinical assets.
Exelixis Announces Third Quarter 2022 Financial Results and Provides Corporate Update
Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the third quarter of 2022 and provided an update on progress toward achieving key corporate objectives, as well as commercial, clinical and pipeline development milestones.
Exelixis and Sairopa Establish Exclusive Clinical Development Collaboration and Option Agreement to Develop ADU-1805, a Potentially Best-in-Class Monoclonal Antibody Targeting SIRPα
Exelixis, Inc. and Sairopa B.V. announced that the companies have entered into an exclusive clinical development and option agreement for ADU-1805, a potentially best-in-class monoclonal antibody that targets SIRPα.
Exelixis and Cybrexa Therapeutics Establish Exclusive Collaboration Providing Exelixis the Right to Acquire CBX-12, a Potential First-in-Class Peptide-Drug Conjugate of Exatecan
Exelixis, Inc. and Cybrexa Therapeutics announced that the companies have entered into an exclusive collaboration agreement providing Exelixis the right to acquire CBX-12, a clinical-stage, first-in-class peptide-drug conjugate that utilizes Cybrexa’s proprietary alphalex technology to enhance delivery of exatecan to tumor cells.
Exelixis Announces Promising Initial Dose-Escalation Results from the First-in-Human Phase 1 JEWEL-101 Trial Evaluating XB002 in Patients with Advanced Solid Tumors at ENA 2022
Exelixis, Inc. announced promising initial results from the ongoing dose-escalation stage of JEWEL-101, a phase 1 study evaluating XB002, Exelixis’ next-generation tissue factor-targeting antibody-drug conjugate.
Exelixis to Release Third Quarter 2022 Financial Results on Tuesday, November 1, 2022
Exelixis, Inc. (Nasdaq: EXEL) announced today that its third quarter 2022 financial results will be released on Tuesday, November 1, 2022 after the markets close.
Exelixis Expands Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb to Include the Fixed-Dose Combination of Nivolumab and Relatlimab in Combination with XL092 in Phase 1b STELLAR-002 Trial
Exelixis, Inc. announced the expansion of its June 2021 Clinical Trial Collaboration and Supply Agreement with Bristol-Myers Squibb Company to include the use of the fixed-dose combination of nivolumab and relatlimab in the ongoing phase 1b STELLAR-002 clinical trial, which is evaluating XL092 in combination with multiple immune checkpoint inhibitors in advanced solid tumors.
Exelixis Announces Dose-Escalation Results from the Phase 1 STELLAR-001 Trial Evaluating XL092 Alone and in Combination with an Immune Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ESMO 2022
Exelixis, Inc. announced results from the dose-escalation stage of STELLAR-001, an ongoing phase 1b trial evaluating XL092 as a single-agent and in combination with atezolizumab in patients with locally advanced or metastatic solid tumors.
Exelixis Announces Detailed Results from Phase 3 COSMIC-313 Pivotal Trial in Patients with Previously Untreated Advanced Kidney Cancer at ESMO 2022
Exelixis, Inc. (Nasdaq: EXEL) today announced detailed results from COSMIC-313, an ongoing phase 3 pivotal trial evaluating the combination of cabozantinib (CABOMETYX®), nivolumab and ipilimumab versus the combination of nivolumab and ipilimumab in patients with previously untreated advanced intermediate- or poor-risk renal cell carcinoma (RCC).
Exelixis To Webcast Fireside Chats as Part of Investor Conferences in September 2022
Exelixis, Inc. announced that members of the company’s management team will participate in fireside chats at the following investor conferences in September.